BIT Biotron Limited
Healthcare · Biotechnology
· website
$0.00
52wk 0.00 – 0.01
Overall
31.3
Value
68.2
Growth
—
Health
33.5
Quality
0.0
Momentum
10.5
Dividend
—
Price
About Biotron Limited
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225 that is in Phase 2 clinical trial for the treatment of HIV-1, as well as to treat hepatitis C virus infections; and BIT-HBV001 to treat hepatitis B virus and hepatitis delta virus. It also develops preclinical drugs for viral diseases, such as dengue, zika, and influenza virus. The company was incorporated in 1999 and is based in Sydney, Australia.
Price analytics
Returns
| 1 day | 0.0% |
| 1 week | 0.0% |
| 1 month | 0.0% |
| 3 months | -20.0% |
| 6 months | -20.0% |
| 1 year | -42.9% |
| 3 years | -98.2% |
Risk
| Volatility (1y ann.) | 223.3% |
| Beta vs ASX 200 | 0.93 |
| Sharpe (1y) | 0.78 |
| VaR 95% (1-day) | -20.0% |
| Max drawdown (1y) | -60.0% |
| Off 1-year high | -60.0% |
Technicals
| RSI(14) | 100 OB |
| vs 50DMA | -2.9% |
| vs 200DMA | -22.0% |
| Trend | Death cross |
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value
68.2
Trailing P/E
—
Forward P/E
—
PEG ratio
—
EV / EBITDA
100
Price / Book
83
Price / Sales
0
Growth
—
Revenue growth (1y)
—
Revenue CAGR (3y)
—
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health
33.5
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
0
Current ratio
67
Debt / Equity
—
Quality (Profitability & Cash Flow)
0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income
—
No meaningful dividend — pillar excluded from the overall score.
Momentum
10.5
6-month return vs ASX 200
0
Price vs 200-day average
0
Price vs 50-day average
35
Position in 52-week range
14
Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).
Score history
Key metrics
Market cap
$5.57M
P/E (trailing)
—
P/E (forward)
—
EPS (trailing)
0.00
Dividend yield
—
Payout ratio
0.0%
Beta
-0.64
EV / EBITDA
-2.58
Price / Book
2.00
ROE
-87.4%
Operating margin
-118.9%
Net margin
-288.7%
Total cash
$1.55M
Total debt
$0
Current ratio
1.94
Debt / Equity
—
Free cash flow
$-588,942
Avg volume
3.41M
Latest annual results
(FY ending 30 Jun 2024)
- Revenue—
- Gross profit—
- Operating income-$5.15M
- Net income-$3.44M
- Diluted EPS-0.00
- Free cash flow-$3.57M
- Net debt-$386.07K